REGENEREX PHARMA, INC.: accrued current liabilities
Accrued current liabilities for REGENEREX PHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All REGENEREX PHARMA, INC. financial histories
What this measure means
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
Exact concept: us-gaap:AccruedLiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-11-30 to 2025-03-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-03-31 | 88,268 | USD | 2025-06-30 | 10-K · 0001472375-25-000070 |
| At date | 2024-03-31 | 97,251 | USD | 2025-06-30 | 10-K · 0001472375-25-000070 |
| At date | 2023-03-31 | 125,787 | USD | 2024-06-24 | 10-K · 0001472375-24-000045 |
| At date | 2022-03-31 | 91,667 | USD | 2023-06-09 | 10-K · 0001472375-23-000090 |
| At date | 2021-03-31 | 71,003 | USD | 2021-06-23 | 10-K · 0001472375-21-000044 |
| At date | 2021-03-21 | 71,003 | USD | 2022-06-28 | 10-K · 0001472375-22-000055 |
| At date | 2020-03-31 | 45,436 | USD | 2021-06-23 | 10-K · 0001472375-21-000044 |
| At date | 2019-03-31 | 14,778 | USD | 2020-08-11 | 10-K/A · 0001472375-20-000042 |
| At date | 2018-03-31 | 10,000 | USD | 2019-06-24 | 10-K · 0001472375-19-000028 |
| At date | 2017-03-31 | 10,000 | USD | 2018-06-21 | 10-K · 0001472375-18-000067 |
| At date | 2014-11-30 | 42,000 | USD | 2015-03-03 | 10-K · 0001472375-15-000062 |
| At date | 2013-11-30 | 27,000 | USD | 2015-03-03 | 10-K · 0001472375-15-000062 |
Related financial histories
- REGENEREX PHARMA, INC.: total assets
- REGENEREX PHARMA, INC.: total liabilities
- REGENEREX PHARMA, INC.: stockholders equity
- REGENEREX PHARMA, INC.: cash and cash equivalents
- REGENEREX PHARMA, INC.: net income or loss
- REGENEREX PHARMA, INC.: operating cash flow
- REGENEREX PHARMA, INC.: financing cash flow
- REGENEREX PHARMA, INC.: investing cash flow
- REGENEREX PHARMA, INC.: retained earnings or deficit
- REGENEREX PHARMA, INC.: basic weighted-average shares
- REGENEREX PHARMA, INC.: share-based compensation expense
- REGENEREX PHARMA, INC.: operating income or loss
- REGENEREX PHARMA, INC.: current assets
- REGENEREX PHARMA, INC.: interest expense
- REGENEREX PHARMA, INC.: current liabilities
- REGENEREX PHARMA, INC.: current accounts payable
- REGENEREX PHARMA, INC.: net finite-lived intangible assets
- REGENEREX PHARMA, INC.: operating expenses
- REGENEREX PHARMA, INC.: common shares outstanding
- REGENEREX PHARMA, INC.: cash including restricted cash
- REGENEREX PHARMA, INC.: additional paid-in capital
- REGENEREX PHARMA, INC.: accumulated depreciation on property, plant and equipment
- REGENEREX PHARMA, INC.: profit or loss including noncontrolling interests
- REGENEREX PHARMA, INC.: general and administrative expense
- REGENEREX PHARMA, INC.: depreciation expense
- REGENEREX PHARMA, INC.: amortization of intangible assets
- REGENEREX PHARMA, INC.: nonoperating income or expense
- REGENEREX PHARMA, INC.: change in accounts payable
Inspect the source
- Entity
- REGENEREX PHARMA, INC. / CIK 0001357878
- Captured
- 2026-09-21T17:18:44.819Z
- SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))